Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	United Therapeutics	Mirati Therapeutics	Evotec	Ascendis Pharma A/S	Arrowhead Pharmaceuticals
Symbol	NASDAQ:UTHR	NASDAQ:MRTX	OTCMKTS:EVTCY	NASDAQ:ASND	NASDAQ:ARWR
Price Information
Current Price	$181.93	$160.06	$81.57	$118.19	$69.29
50-Day Moving Average	$181.89	$162.36	$85.76	$129.41	$74.89
52-Week Low	$98.37	$117.68	$51.35	$109.36	$32.86
52-Week High	$212.62	$249.42	$91.26	$183.98	$93.66
MarketRank™
Overall Score	2.5	1.8	0.9	2.6	2.0
Analysis Score	2.5	3.3	0.0	4.5	2.4
Community Score	4.0	4.9	4.5	4.7	4.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	3.3	0.8	0.0	3.3	2.5
Earnings & Valuation Score	2.5	0.0	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$224.38	$217.92	N/A	$192.00	$86.45
% Upside from Price Target	23.33% upside	36.15% upside	N/A	62.45% upside	24.77% upside
Trade Information
Market Cap	$8.15 billion	$8.23 billion	$6.71 billion	$6.36 billion	$7.21 billion
Beta	0.49	1.33	1	0.75	1.26
Average Volume	197,323	293,916	335	185,042	1,094,898
Sales & Book Value
Annual Revenue	$1.48 billion	$13.40 million	$572.16 million	$7.94 million	$87.99 million
Price / Sales	5.49	614.44	11.73	801.28	81.96
Cashflow	$12.55 per share	N/A	$0.87 per share	N/A	N/A
Price / Cash	14.50	N/A	93.68	N/A	N/A
Book Value	$76.40 per share	$26.98 per share	$10.07 per share	$17.94 per share	$4.51 per share
Price / Book	2.38	5.93	8.10	6.59	15.36
Profitability
Net Income	$514.80 million	$-357,940,000.00	$7.14 million	$-478,570,000.00	$-84,550,000.00
EPS	$11.54	($7.96)	N/A	($9.46)	($0.84)
Trailing P/E Ratio	20.10	N/A	135.95	N/A	N/A
Forward P/E Ratio	12.58	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	26.92%	N/A	8.56%	-7,700.88%	-122.97%
Return on Equity (ROE)	12.27%	-43.11%	7.21%	-54.80%	-23.64%
Return on Assets (ROA)	9.07%	-39.31%	3.30%	-47.37%	-18.78%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.23%	N/A	0.61%	N/A	N/A
Current Ratio	6.66%	16.91%	2.84%	9.42%	3.51%
Quick Ratio	6.36%	16.91%	2.78%	9.42%	3.51%
Ownership Information
Institutional Ownership Percentage	94.99%	N/A	N/A	98.29%	65.07%
Insider Ownership Percentage	12.00%	3.12%	N/A	40.00%	3.50%
Miscellaneous
Employees	950	199	3,572	482	147,000
Shares Outstanding	44.80 million	51.44 million	82.29 million	53.83 million	104.08 million
Next Earnings Date	8/4/2021 (Confirmed)	8/5/2021 (Estimated)	8/11/2021 (Estimated)	8/26/2021 (Estimated)	8/5/2021 (Confirmed)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Asso us.acrofan.com - July 29 at 8:22 AM
	Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease finance.yahoo.com - July 29 at 8:22 AM
	Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) nasdaq.com - July 17 at 6:30 PM
	$50.20 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter americanbankingnews.com - July 11 at 2:20 AM
	Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright markets.businessinsider.com - July 6 at 6:16 PM
	Arrowhead Pharmaceuticals Inc. [ARWR] Stock trading around $63.13 per share: What’s Next? dbtnews.com - July 6 at 6:16 PM
	Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sees Large Volume Increase americanbankingnews.com - July 6 at 11:43 AM
	Mid-day market update: Dow surges over 100 points, Arrowhead Pharmaceuticals shares plummet fxstreet.com - July 2 at 1:04 PM
	B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals investing.com - July 2 at 1:04 PM
	Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment thestreet.com - July 2 at 1:04 PM
	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Making Its Way Up the Stock Market stocksregister.com - July 2 at 1:04 PM
	ARWR Jul 2021 80.000 call uk.finance.yahoo.com - June 28 at 2:01 PM
	Arrowhead Presents Additional Clinical Data on... benzinga.com - June 26 at 2:05 PM
	H.C. Wainwright Stick to Their Buy Rating for Arrowhead Pharmaceuticals investing.com - June 25 at 1:03 PM
	Notable ETF Outflow Detected - IWO, RH, DECK, ARWR nasdaq.com - June 25 at 1:03 PM
	Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress finance.yahoo.com - June 25 at 8:02 AM
	Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress finance.yahoo.com - June 23 at 7:48 AM
	Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Shares Plunges -3.46% In A Week – But Can It Keep Rising? marketingsentinel.com - June 19 at 2:50 PM
	Read This Before Buying Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares nasdaq.com - June 13 at 12:06 PM
	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): What It’s Worth And What To Do About It marketingsentinel.com - June 5 at 1:25 PM
	Arrowhead Receives $10M Option Exercise Fee From Janssen finance.yahoo.com - May 18 at 1:52 PM
	Arrowhead Earns $10 Million Option Exercise Fee finance.yahoo.com - May 18 at 8:51 AM
	Leerink Partners Stick to Their Hold Rating for Arrowhead Pharmaceuticals investing.com - May 9 at 10:13 AM
	Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript seekingalpha.com - May 6 at 7:29 PM
	Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results finance.yahoo.com - May 4 at 7:17 PM

Date	Company	Brokerage	Action
7/21/2021	Ascendis Pharma A/S	SVB Leerink	Lower Price Target
7/14/2021	United Therapeutics	Argus	Upgrade
7/8/2021	Ascendis Pharma A/S	Oppenheimer	Reiterated Rating
7/2/2021	Arrowhead Pharmaceuticals	HC Wainwright	Reiterated Rating
7/2/2021	Arrowhead Pharmaceuticals	Piper Sandler	Lower Price Target
6/27/2021	Arrowhead Pharmaceuticals	SVB Leerink	Reiterated Rating
6/21/2021	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
6/14/2021	Ascendis Pharma A/S	SVB Leerink	Lower Price Target
6/14/2021	Ascendis Pharma A/S	Wedbush	Lower Price Target
6/14/2021	Ascendis Pharma A/S	Morgan Stanley	Lower Price Target
6/4/2021	Mirati Therapeutics	Citigroup	Upgrade
6/1/2021	Ascendis Pharma A/S	Canaccord Genuity	Boost Price Target
5/28/2021	Ascendis Pharma A/S	Credit Suisse Group	Boost Price Target
5/28/2021	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
5/24/2021	Mirati Therapeutics	Oppenheimer	Reiterated Rating
5/17/2021	Mirati Therapeutics	Oppenheimer	Downgrade
5/11/2021	Evotec	Royal Bank of Canada	Upgrade
5/10/2021	Mirati Therapeutics	HC Wainwright	Lower Price Target
5/10/2021	Mirati Therapeutics	Jefferies Financial Group	Upgrade
5/6/2021	United Therapeutics	HC Wainwright	Boost Price Target
4/22/2021	Evotec	Deutsche Bank Aktiengesellschaft	Reiterated Rating
4/8/2021	United Therapeutics	JPMorgan Chase & Co.	Boost Price Target
3/30/2021	Ascendis Pharma A/S	Oppenheimer	Downgrade
3/12/2021	Ascendis Pharma A/S	Canaccord Genuity	Boost Price Target
3/11/2021	Ascendis Pharma A/S	Credit Suisse Group	Lower Price Target
3/11/2021	Ascendis Pharma A/S	Stifel Nicolaus	Initiated Coverage
3/5/2021	Evotec	Citigroup	Downgrade
3/1/2021	Mirati Therapeutics	Oppenheimer	Lower Price Target
3/1/2021	Mirati Therapeutics	HC Wainwright	Lower Price Target
2/25/2021	United Therapeutics	Wedbush	Boost Price Target
2/22/2021	United Therapeutics	Credit Suisse Group	Boost Price Target
2/16/2021	United Therapeutics	Oppenheimer	Boost Price Target
2/8/2021	Arrowhead Pharmaceuticals	Citigroup	Boost Price Target
2/8/2021	Arrowhead Pharmaceuticals	B. Riley	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Chardan Capital	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	HC Wainwright	Boost Price Target
2/1/2021	United Therapeutics	HC Wainwright	Upgrade
1/28/2021	Evotec	Royal Bank of Canada	Downgrade
1/20/2021	United Therapeutics	Oppenheimer	Boost Price Target
1/20/2021	United Therapeutics	Cowen	Boost Price Target
1/20/2021	United Therapeutics	LADENBURG THALM/SH SH	Boost Price Target
1/19/2021	Evotec	Deutsche Bank Aktiengesellschaft	Downgrade
1/15/2021	Mirati Therapeutics	HC Wainwright	Lower Price Target
12/21/2020	Arrowhead Pharmaceuticals	Robert W. Baird	Downgrade
12/17/2020	Ascendis Pharma A/S	Berenberg Bank	Initiated Coverage
12/16/2020	Mirati Therapeutics	Credit Suisse Group	Boost Price Target
12/15/2020	Arrowhead Pharmaceuticals	UBS Group	Initiated Coverage
12/8/2020	Mirati Therapeutics	Evercore ISI	Initiated Coverage
12/8/2020	Mirati Therapeutics	JMP Securities	Initiated Coverage
11/24/2020	Arrowhead Pharmaceuticals	Royal Bank of Canada	Boost Price Target
11/24/2020	Arrowhead Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
11/24/2020	Arrowhead Pharmaceuticals	SVB Leerink	Lower Price Target
11/20/2020	Evotec	Royal Bank of Canada	Reiterated Rating
11/19/2020	Arrowhead Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
11/17/2020	Mirati Therapeutics	Bank of America	Downgrade
11/17/2020	Arrowhead Pharmaceuticals	B. Riley	Boost Price Target
11/16/2020	Arrowhead Pharmaceuticals	Robert W. Baird	Boost Price Target
11/13/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
11/12/2020	Ascendis Pharma A/S	Wells Fargo & Company	Boost Price Target
11/12/2020	Ascendis Pharma A/S	Credit Suisse Group	Boost Price Target
11/12/2020	Ascendis Pharma A/S	SVB Leerink	Boost Price Target
11/10/2020	Mirati Therapeutics	Jefferies Financial Group	Downgrade
11/10/2020	Mirati Therapeutics	Guggenheim	Downgrade
11/9/2020	Mirati Therapeutics	HC Wainwright	Boost Price Target
11/5/2020	Mirati Therapeutics	Oppenheimer	Boost Price Target
11/5/2020	Mirati Therapeutics	Piper Sandler	Boost Price Target
11/2/2020	Mirati Therapeutics	HC Wainwright	Lower Price Target
10/29/2020	United Therapeutics	Wedbush	Boost Price Target
10/29/2020	United Therapeutics	Oppenheimer	Boost Price Target
10/29/2020	Mirati Therapeutics	Barclays	Boost Price Target
10/27/2020	Mirati Therapeutics	Credit Suisse Group	Boost Price Target
10/26/2020	Mirati Therapeutics	Oppenheimer	Boost Price Target
10/26/2020	Mirati Therapeutics	SVB Leerink	Boost Price Target
10/26/2020	Mirati Therapeutics	The Goldman Sachs Group	Boost Price Target
10/26/2020	Mirati Therapeutics	HC Wainwright	Boost Price Target
10/26/2020	Mirati Therapeutics	Piper Sandler	Boost Price Target
10/13/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
10/12/2020	Arrowhead Pharmaceuticals	B. Riley	Boost Price Target
10/12/2020	Arrowhead Pharmaceuticals	HC Wainwright	Reiterated Rating
10/8/2020	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
9/30/2020	Ascendis Pharma A/S	Wedbush	Boost Price Target
9/17/2020	Arrowhead Pharmaceuticals	SVB Leerink	Boost Price Target
9/14/2020	United Therapeutics	JPMorgan Chase & Co.	Initiated Coverage
9/14/2020	Ascendis Pharma A/S	JPMorgan Chase & Co.	Initiated Coverage
9/10/2020	Evotec	Royal Bank of Canada	Initiated Coverage
9/1/2020	Evotec	Citigroup	Initiated Coverage
8/31/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
8/28/2020	Ascendis Pharma A/S	Credit Suisse Group	Boost Price Target
8/24/2020	Arrowhead Pharmaceuticals	HC Wainwright	Reiterated Rating
7/30/2020	United Therapeutics	Oppenheimer	Boost Price Target
7/29/2020	United Therapeutics	Wedbush	Reiterated Rating
7/29/2020	Arrowhead Pharmaceuticals	Chardan Capital	Reiterated Rating
7/15/2020	Ascendis Pharma A/S	Morgan Stanley	Lower Price Target
6/26/2020	Ascendis Pharma A/S	Wedbush	Initiated Coverage
6/25/2020	United Therapeutics	Wedbush	Reiterated Rating
6/25/2020	United Therapeutics	Credit Suisse Group	Boost Price Target
6/25/2020	United Therapeutics	HC Wainwright	Boost Price Target
6/24/2020	United Therapeutics	Oppenheimer	Initiated Coverage
6/17/2020	United Therapeutics	Wedbush	Reiterated Rating
6/12/2020	United Therapeutics	Cowen	Reiterated Rating
5/21/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
5/12/2020	Arrowhead Pharmaceuticals	Royal Bank of Canada	Initiated Coverage
5/10/2020	Arrowhead Pharmaceuticals	B. Riley	Reiterated Rating
4/30/2020	United Therapeutics	Wedbush	Reiterated Rating
4/30/2020	United Therapeutics	Credit Suisse Group	Reiterated Rating
3/12/2020	Evotec	Deutsche Bank Aktiengesellschaft	Reiterated Rating
3/10/2020	United Therapeutics	Jefferies Financial Group	Upgrade
3/4/2020	United Therapeutics	Wedbush	Reiterated Rating
8/21/2019	Evotec	Deutsche Bank Aktiengesellschaft	Upgrade
4/10/2019	Evotec	Deutsche Bank Aktiengesellschaft	Downgrade

(Data available from 7/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources